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1. Introduction 
1.1 Importance of cardiovascular disease and scope of this chapter 
Cardiovascular disease, diabetes, and obesity are important causes of morbidity and 
mortality. Cardiovascular disease affects 80 million Americans and is the leading cause of 
death (Lloyd-Jones et al., 2009). Diabetes and obesity are also increasing at alarming rates, 
and together, the three conditions have a significant impact on public health (Ogden et al., 
2006). Cardiovascular disease, diabetes and obesity can be influenced by lifestyle changes, 
including diet and physical activity (McCullough et al., 2000). The American Heart 
Association recommends a diet rich in vegetables and fruits, whole grains, high-fiber foods, 
with lean meats and poultry, moderate consumption of fish, an emphasis on fat-free or low 
fat dairy products, and limiting the amount of saturated fat, trans fat and cholesterol 
(Lichtenstein et al., 2006).  
Among natural products found in food, fish oils, vitamin E, and soy isoflavones have been 
studied for their effects on cardiovascular disease. Many of these compounds are available 
as food supplements. There is a great interest among the public and in the lay press about 
the use of these compounds to treat or prevent disease. The scope of this chapter is to review 
the evidence for the effects of these compounds on cardiovascular disease, so that physicians 
and patients may better understand their health effects, in an effort to reduce the risk for 
cardiovascular disease, diabetes and obesity.  
1.2 Types of evidence: Epidemiologic, mechanistic, and randomized clinical trials 
It is important to realize the different kinds of evidence in support of health benefits of 
natural products. One type of evidence is epidemiologic evidence. Epidemiologic information 
may offer the first suggestion that certain natural products in the diet may influence the risk 
and course of chronic diseases like cardiovascular disease, diabetes, and cancer. Cross-
cultural studies might indicate that populations that have high or low intake of certain 
compounds have different incidence of cardiovascular disease. This does not prove that 
supplementation with these compounds would necessarily change the course of 
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cardiovascular disease. Genetic and environmental factors may all contribute to the effects 
observed in the epidemiologic studies. Cohort studies, which follow groups of people and 
their intake of certain compounds, also provide suggestive evidence for their effects.  
A second type of evidence comes from mechanistic studies in the laboratory or in animal 
models. Here, the natural products or compounds in question are added to cells or enzyme 
reactions, to see what their effects are. Studies may be done in animal models of human 
disease, for example apoE knockout mice that develop diet-induced atherosclerosis. They may 
be carried out on blood vessels from animals to see whether the compounds affect vascular 
function. Mechanistic studies help determine the possible molecular and cellular mechanisms 
and pathways involved in biological function. However, just because a compound has an 
effect in these experiments or animals models does not mean that taking them will necessarily 
reduce disease in people. Many of these experiments are done in vitro, not in vivo.  
A third type of evidence comes from randomized controlled clinical trials. In these trials, 
compounds are administered to a large population, which is then followed for clearly 
defined disease events. Randomized clinical trials offer the strongest scientific evidence for 
or against health benefits. These studies often use pure compounds or standardized 
preparations. Often, compounds for which epidemiologic studies suggest benefit, and 
mechanistic studies show effects, fail to do so in large randomized clinical trials. There have 
also been surprising results of increased disease risk from certain natural products, 
suggesting the need for caution and for ongoing studies to obtain evidence of the best 
possible quality. It is important to approach results of studies with a critical eye, and to 
always consider the quality of the information and how strongly it supports an effect.  
In this article, three specific classes of compounds—omega-3 fatty acids, vitamin E, and soy 
isoflavones—are reviewed. Evidence for their biological effects are presented, categorized 
separately according to type of evidence: epidemiological studies, mechanistic studies, and 
where available, randomized controlled trials. It is hoped that this review will provide the 
basis for evidence-based recommendations to patients regarding these compounds and food 
supplements.  
2. Fish oils: Omega-3 fatty acids 
2.1 Structure and food sources 
While many fatty acids serve as energy stores that are broken down by the body to generate 
energy, omega-3 and omega-6 fatty acids are two types of polyunsaturated fatty acids that 
serve as precursors to biologically active molecules, including prostaglandins, leukotrienes, 
and thromboxanes. This role gives them particular importance in the diet.  
Polyunsaturated fatty acids are a family of long-chain (typically 18-24 carbon atoms) fatty 
acids containing two or more double bonds. Omega-3 and omega-6 refer to the position of 
the last double bond. The convention in chemical nomenclature is to label the COOH carbon 
as the first carbon, and the one furthest from this as the last, or omega, carbon. Thus, omega-3 
fatty acids contain a double bond three carbons from the end of the molecule furthest from 
the COOH group. Given that the length of the hydrocarbon chain is variable, the length is 
sometimes referred to as “n,” so omega-3 fatty acids are also known as n-3 fatty acids, and 
omega-6 fatty acids as n-6 fatty acids. 
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Fig. 1. Structures of omega-6 and omega-3 fatty acids 
Omega-3 fatty acids differ from omega-6 fatty acids by the location of their first double bond 
from the methyl (CH3) end of the fatty acid. Omega-3 fatty acids include -linolenic acid 
(ALA), eicosapentanoic acid (EPA), and docosahexanoic acid (DHA). Omega-6 fatty acids 
include linoleic acid (LA), arachidonic acid (AA), and docosapentanoic acid (DPA). In the 
chemical names, the number of carbon atoms is given first, separated by a colon from the 
number of double bonds, followed by the position of the first double bond. 
The structures of omega-3 and omega-6 fatty acids are shown in Figure 1. Representative 
omega-3 fatty acids are -linolenic acid (ALA), eicosapentanoic acid (EPA), and 
docosahexanoic acid (DHA). Of these, the parent omega-3 fatty acid is ALA, an 18 carbon 
fatty acid with three double bonds, the last of which is located between carbons 15 and 16 
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(the n-3 position). Therefore, in shorthand, ALA is C18:3 n-3. ALA serves as the precursor to 
the omega-3 fatty acids EPA (C20:5 n-3) and DHA (C22:6 n-3) by the addition of carbons to 
the chain (elongation) and by the replacement of single bonds by double bonds 
(desaturation). Likewise, representative omega-6 fatty acids are linoleic acid (LA), 
arachidonic acid (AA), and docosapentanoic acid. LA is an 18 carbon fatty acid with two 
double bonds, with the last one located at the n-6 position (C18:2 n-6). LA serves as a 
precursor to AA (C20:4 n-6) and docosapentanoic acid (C22:5 n-6), which are formed by 
elongation and desaturation. 
The parent fatty acids of the omega-3 family (ALA) and omega-6 family (LA) cannot be 
made by the human body, so they are essential fatty acids. They must be supplied in the diet. 
LA is found in vegetable oils like soybean and canola, and also in nuts, seeds, vegetables, 
legumes, grains, and fruit. ALA is found in vegetable sources like flaxseed, but only 5% of 
ALA is converted to DHA and EPA. The richest sources of DHA and EPA are fish and fish 
oils.  
2.2 Biological roles of omega-3 and omega-6 fatty acids 
Omega-3 and -6 fatty acids are important biologically because they influence production of 
prostaglandins, leukotrienes, and thromboxanes. These mediators affect many diverse 
processes, and are involved in inflammation, pain, and thrombosis (Calder, 2006). 
Moreover, omega-3 and omega-6 fatty acids are separate families that cannot be 
interconverted by the human body. Because they compete for the same enzymes, the ratio of 
omega-3 to omega-6 fatty acids in the diet influences the relative amounts of prostaglandins 
and leukotrienes that are synthesized from arachidonic acid.  
2.3 Epidemiologic data on fish oils and cardiovascular disease 
Epidemiologic data from fish-eating populations like the Greenland Inuits established a link 
between fish oil consumption and lower incidence of cardiovascular disease (Dyerberg et 
al., 1975). Fish oil consumption was also linked with low levels of triglycerides, plasma 
cholesterol and very low-density lipoproteins (VLDL) and high levels of high-density 
lipoproteins (HDL), all of which would protect against cardiovascular disease.  
2.4 Mechanistic studies 
Omega-3 fatty acids may influence cardiovascular disease through effects on lipid profiles, 
eicosanoid pathways, and susceptibility to arrythmias.  
2.4.1 Lipid profiles 
Omega-3 fatty acids decrease plasma cholesterol concentrations in animal models 
(Fernandez & West, 2005). They increase hepatic LDL receptor number and LDL turnover in 
vivo (Fernandez & McNamar, 1989, Fernandez et al., 1992), and bind to peroxisome 
proliferator activated receptors (PPARs), liver X receptors (LXRs), hepatic nuclear factor-4 
(HNF-4), and sterol regulatory element binding proteins (SREBPs) (Jump, 2002). Omega-3 
fatty acids suppress SREBP-1 expression, leading to decreased lipogenesis and VLDL 
secretion (Field et al., 2003), increased LPL activity (Illingworth & Schmidt, 1993), and 
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decreased apoC3 levels (Shachter, 2001). They also decrease lipogenesis and VLDL secretion 
while increasing reverse cholesterol transport (Vasandani et al., 2002). 
2.4.2 Eicosanoid metabolism 
Omega-3 and omega-6 fatty acids are precursors to a broad array of structurally diverse and 
potent bioactive lipids, including eicosanoids, prostaglandins, and thromboxanes. 
Eicosanoids are produced from arachidonic acid, EPA, and dihomolinolenic acid when these 
fatty acids are released from membranes by phospholipase A2 (Zhou & Nilsson, 2001). The 
availability of these eicosanoid precursors depends on dietary levels of these molecules, as 
well as the parent fatty acids of each family: ALA for omega-3 fatty acids, and LA for 
omega-6 fatty acids. Because omega-6 and omega-3 fatty acids cannot be interconverted, 
their relative ratios are important.  
Arachidonic acid, an omega-6 fatty acid, is a precursor of prostaglandins, leukotrienes and 
related compounds that mediate inflammation. Because omega-3 fatty acids compete with 
omega-6 fatty acid metabolism, increased consumption of omega-3 fatty acids (particularly 
DHA and EPA) results in the partial replacement of arachidonic acid in cell membranes by 
EPA and DHA, and a decrease in the production of biological mediators derived from AA. 
Intake of 6 g DHA/d decreased production of prostaglandin E2 by 60% and leukotriene B4 
by 75% in endotoxin-stimulated mononuclear cells (Kelley et al., 1999). Other studies have 
shown a shift in the relative amounts of prostaglandin I2 and thromboxane A2, resulting in 
vasodilation and reduced thrombosis (von Schacky et al., 1985, Goodnight et al., 1989). 
Omega-3 fatty acids, particularly DHA and EPA in fish oil, may themselves reduce 
expression of ICAM-1 on the surface of stimulated blood monocytes (Hughes et al., 1996), 
and decrease hydrogen peroxide production (Fisher et al., 1990).  
2.4.3 Antiarrhythmic effects 
DHA and EPA may be preferentially incorporated into membrane phospholipids, 
accounting for an antiarrhythmic effect after dietary intake (Nair et al., 1999). These fatty 
acids directly influence conduction of several membrane ion channels (Leaf et al., 2003), 
inhibit voltage-gated sodium currents and L-type calcium currents (Kang et al., 1995), and 
shift the steady-state inactivation potential to more negative values in cardiomyocytes. 
These results provide an electrophysiological basis for antiarrhythmic effects.  
2.5 Clinical studies 
Dietary intake of omega-3 fatty acids, particularly DHA and EPA found in fatty fish or fish-
oil supplements, reduces risk of CVD (Kris-Etherton et al., 2002, Wang et al., 2006). The 
strongest evidence comes from the Italian GISSI trial (1999), a secondary prevention study in 
over 11,000 patients with recent myocardial infarction. Supplementation with 0.85 g EPA 
and DHA per day reduced all-cause mortality by 21%, cardiac death by 35%, and sudden 
death by 45%. No effect was found on stroke. In contrast, a Norwegian study of 300 patients 
following MI, randomized to a higher intake of omega-3 fatty acids (3.4 g EPA and DPA per 
day), failed to show a difference in CVD events, but there was a high background of fish oil 
intake in both groups. Several other small studies suggested beneficial trends in CVD and 
PVD, but these were not statistically significant (Sacks et al., 1995, Nilsen et al., 2001).  
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In these studies, patients with implantable cardiac defibrillators (ICD) were excluded. 
Several randomized controlled trials, ranging in size from 200 to over 500 patients, studied 
fish oil consumption in patients with ICDs (Raitt et al., 2005,Brouwer et al., 2006). These 
studies showed no change in mortality from fish oil consumption. It is possible that the 
beneficial effects of fish oils may not be observed in the ICD population, because these 
patients all have defibrillators and therefore cardiac arrhythmic sudden death would be 
removed from both groups.  
Primary prevention trials, which study patients in the general population who do not have 
known heart disease, have not shown as strong an effect as the GISSI trial. Most primary 
prevention data on fish oils comes from large cohort studies from China, Japan, and the 
United States (Dolecek, 1992, Nagata et al., 2002) and others. In aggregate, these studies 
included over 343,000 subjects, and showed reductions in all-cause mortality, cardiac 
mortality, and sudden death. Interestingly, in one of these studies (Mozaffarian et al., 2003), 
the protection was found with tuna and other nonfried fish, while consumption of fried fish 
or fried fish sandwiches was associated with increased cardiovascular events. 
3. Vitamin E 
3.1 Structure and food sources 
Vitamin E is a fat-soluble vitamin that exists in at least eight naturally occurring forms, as 
shown in Figure 2. Tocotrienols differ from tocopherols by the presence of three double 
bonds in their isoprenoid side chains. The -, -, -, and - forms are defined by the identity 
of the R groups on the chromanol rings. Vitamin E found naturally in food is primarily -
tocopherol, but -tocopherol is the predominant form found in supplements, and is also the 
most biologically active form.  
Vitamin E is an essential vitamin because it cannot be synthesized by the body. Sources of 
vitamin E include nuts and seeds, such as almonds, peanuts, sunflower seeds, and filberts.  
Tocopherols are similar in structure to tocotrienols, except that tocotrienols have three 
double bonds in the phytyl side chains. There are three positions on the chromanol ring, 
denoted R1, R2, and R3. The particular identity of the tocopherol or tocotrienol is determined 
by the identities of these side chains. Vitamin E found naturally in food is primarily -
tocopherol. -tocopherol, which is the most biologically active, is the predominant form 
found in supplements.  
Vitamin E is also found in vegetable oils (soy, corn or sunflower), and their derivatives 
(margarine), cereals and grains. Vitamin E is found in potato chips and tomato products 
because of the vegetable oils that they contain.  
3.2 Biological roles of vitamin E 
Vitamin E is an antioxidant, because it breaks chain reactions that are propagated by free 
radicals. Vitamin E is present in biological membranes, and serves as an important lipid 
soluble antioxidant. It reacts with oxidant molecules and protects cell membranes from lipid 
peroxidation by trapping peroxyl radicals. One molecule of -tocopherol per 1,000 
phospholipids can protect cellular membranes. -tocopherol can also be regenerated from 
its tocopheroxyl radical by an electron donor like vitamin C.  
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Fig. 2. Structures of tocopherols and tocotrienols 
3.3 Epidemiologic data on vitamin E and cardiovascular disease 
High intake of vitamin E is epidemiologically associated with lower cardiovascular disease 
risk. The World Health Organization/Monica project performed cross-cultural analysis on 
vitamin intake in populations with different incidence of coronary heart disease mortality. 
Differences in cardiovascular mortality were primarily attributable to plasma levels of 
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vitamin E in middle-aged men representing 16 European study populations (Gey et al., 
1991).  
Several cohort studies showed similar results. The US Nurse’s Health Study followed a 
cohort of 87,245 female nurses between the ages of 34 and 59 years, over an eight year 
period. Supplementation with -tocopherol for at least two years was associated with 
reduced risk of cardiovascular disease (Stampfer et al., 1993). Incidence of heart disease was 
30-40% lower in those with the highest intakes of vitamin E. Another cohort study followed 
39,910 male health professionals between the ages of 40 and 75. Consumption of more than 
60 IU/d of vitamin E was associated with a 40% relative risk reduction of cardiovascular 
disease (Rimm et al., 1993). Vitamin E intake from food was inversely associated with CVD 
risk in 34,486 postmenopausal women (Kushi et al., 1996).  
3.4 Mechanistic studies 
In ex vivo human studies, monocytes isolated from healthy human subjects supplemented 
with -tocopherol showed decreased LDL oxidation (Devaraj et al., 1996). In other studies, 
vitamin E supplementation failed to affect lipid oxidation, including isoprostanes and 4-
hydroxynonenal (breakdown products of fatty acid autooxidation) (Meagher et al., 2001). 
One animal study showed that vitamin E intake inversely correlates with atherosclerotic 
lesions and liver peroxidation in apoE knockout mice (Ferre et al., 2001). In another study, 
vitamin E and coenzyme Q (CoQ) supplementation significantly reduced tissue lipid 
hydroperoxide formation and limited the development of atherosclerosis in apoE knockout 
mice (Thomas et al., 2001). However, still other studies found that vitamin E did not reduce 
atherosclerosis in apoE knockout mice (Paul et al., 2001), or fatty streak formation in 
C57/Bl6 mice (Munday et al., 1998). The degree of lipid oxidation in vascular tissue also 
failed to correlate with the extent of the lesions in apoE knockout mice (Wu et al., 2006). 
Thus, animal studies do not show uniform benefit of vitamin E supplementation in 
preventing LDL oxidation or reducing atherosclerosis. 
3.5 Clinical trials on vitamin E  
3.5.1 Vitamin E and cardiovascular disease 
Some clinical trials suggest a benefit of vitamin E in reducing cardiovascular disease. The 
Cambridge Heart Antioxidant Study (CHAOS) randomized 2,002 patients with coronary 
disease to -tocopherol (400 to 800 IU) or placebo. The vitamin E treated groups showed 1.9 
fold reductions in cardiovascular death and nonfatal myocardial infarction (Stephens et al., 
1996). The Secondary Prevention with Antioxidants of Cardiovascular Disease in End-stage 
Renal Disease (SPACE) trial randomized 192 renal failure patients undergoing hemodialysis 
to 800 IU vitamin E or placebo. The vitamin E treated group showed a significant decrease 
in both fatal and nonfatal cardiovascular endpoints (Boaz et al., 2000).  
Other clinical trials failed to show benefit. In the GISSI study, 11,324 patients were given 
omega-3 fatty acids, vitamin E at 300 mg per day, both, or neither, and followed over a 3½ 
year period. Two-way analysis did not show any reduction in fatal or nonfatal 
cardiovascular events from vitamin E supplementation (Marchioli et al., 2002), (1999). The 
Heart Outcomes Prevention Evaluation (HOPE) trial was a multinational study of over 9,500 
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patients with known cardiovascular disease, randomized to the angiotensin converting 
enzyme inhibitor ramipril, natural source vitamin E at 400 IU per day, both, or neither. Over 
a 4½ year follow-up, there was no reduction in fatal or nonfatal cardiovascular events in the 
vitamin E treated groups (Yusuf et al., 2000). In an extension study (HOPE –TOO), almost 
4000 subjects continued to take vitamin E or placebo for an additional 2½ years (Lonn et al., 
2005). Despite this 7 year total follow-up period, there was no significant protection against 
cardiovascular disease, stroke, or death.  
Of concern, the HOPE-TOO study showed a higher incidence of heart failure in the 
treated group. In the Women’s Angiographic Vitamin and Estrogen Study, 423 post-
menopausal women with coronary disease took supplements with 400 IU vitamin E or 
placebo (Waters et al., 2002). Not only did women taking vitamin E not show 
cardiovascular benefit, but there was an increase in all-cause mortality. In the Physicians 
Health Study II, 15,000 health physicians age 50 or over were randomized to -tocopherol 
(400 IU), 500 mg vitamin C, both, or placebo (Sesso et al., 2008). Over a follow-up period 
of 8 years, neither vitamin E nor vitamin C resulted in a decrease in cardiovascular events, 
stroke, or cardiovascular mortality. In contrast, -tocopherol was associated with an 
increase in hemorrhagic stroke. Taking the results of all of these results together, 
including a meta-analysis (Miller et al., 2005), vitamin E is not recommended for the 
purpose of reducing cardiovascular risk.  
3.5.2 Vitamin E and diabetes 
Oxidative stress and inflammation have been implicated in the pathogenesis of diabetes(Ho 
& Bray, 1999). Vitamin E treatment (600 mg per day) improved insulin-mediated glucose 
disposal in 36 healthy, nondiabetic volunteers (Facchini et al., 2000). A prospective cohort 
study showed that plasma concentration of -tocopherol was inversely related to fasting 
plasma glucose concentration and oxidative stress markers in 101 women at high risk of 
type 2 diabetes in Finland (Ylonen et al., 2003). In secondary prevention trials, 600 mg/day 
of vitamin E supplementation significantly decreased markers of oxidative stress and 
improved brachial artery reactivity in 40 patients with diabetes (Paolisso et al., 2000). 
However, the Insulin Resistance and Atherosclerosis Study (IRAS) cohort study showed no 
protective effect for either reported intake of vitamin E or plasma concentration of -
tocopherol in 895 nondiabetic adults (Mayer-Davis et al., 2002). In another study, high levels 
of -tocopherol and -carotene were associated with decreased risk of non-insulin 
dependent diabetes mellitus, but the association disappeared after adjustment for 
cardiovascular risk factors (Reunanen et al., 1998). Whether vitamin E influences the 
development of diabetes is not clear and warrants further investigation. 
4. Phytoestrogens 
4.1 Structure and food sources of phytoestrogens 
Phytoestrogens are flavonoids that have similar chemical structure to estrogen. They include 
isoflavones, coumestans, and lignans (Kurzer & Xu, 1997). Figure 3 shows a comparison of 
the chemical structures of estradiol (a naturally occurring human estrogen), genistein (an 
isoflavone), and coumestrol (a coumestan). A number of these compounds have been 
identified in fruits, vegetables, and whole grains commonly consumed as food. Soybeans, 
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clover and alfalfa sprouts, and oilseeds (such as flaxseed) are the most significant dietary 
sources. 
 
Fig. 3. Structures of isoflavones and coumestans compared with estrogen 
The structure of estradiol, a natural estrogen, is shown along with the structures of 
genistein, a prototypic isoflavone found in soy, and coumestrol, a prototypic coumestan. 
4.2 Epidemiology data on phytoestrogens and cardiovascular disease 
While typical isoflavone intake is less than 1 mg per day in Western countries, intakes of 20-
50 mg per day are common in Asian countries such as China and Japan, where soy is a 
traditional staple food (Adlercreutz & Mazur, 1997). These countries also have shown 
reduced incidence of cardiovascular disease compared with Western countries, an effect that 
is diminishing as Western eating habits and diets are adopted.  
4.3 Biological activities of phytoestrogens  
Dietary phytoestrogens may play an important role in prevention of menopausal symptoms, 
osteoporosis, cancer, and cardiovascular disease. The major mechanisms of biological action 
for the phytoestrogens are those mediated by estrogen receptors (estrogenic and 
antiestrogenic effects), effects on tyrosine kinase and DNA topoisomerase activities, 
suppression of angiogenesis, and antioxidant effects.  
Although not as active as 17-estradiol, phytoestrogens compete with estradiol for binding 
to estrogen receptors (ER), particularly ER (Kuiper et al., 1998). ER, present in high 
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concentrations in ovary and testis, binds phytoestrogens with higher affinity, and may 
mediate some of their biological effects (Kuiper et al., 1998). Alternatively, soy isoflavones 
may be natural selective estrogen receptor modulators (SERMs) with both agonist and 
antagonist activities (Setchell, 2001). 
Soy isoflavones decrease total cholesterol, LDL, and triglycerides, and increase HDL levels 
(Clarkson et al., 2001). They also lower blood pressure and improve endothelial reactivity 
(Teede et al., 2001, Steinberg et al., 2003). Supplementation of isoflavones derived from red 
clover containing genistein, daidzein, biochanin, and formononetin significantly improved 
arterial compliance in elderly men and women (Nestel et al., 1999).  
Several studies reveal the potential of phytoestrogens to induce hormone-dependent cancers 
(e.g. breast and endometrium) (McMichael-Phillips et al., 1998), leading to safety concerns. 
Because of this, a maximum daily intake level for phytoestrogens has been suggested in 
several countries (Sirtori et al., 2005). 
 
Summary of key points 
Omega-3 fatty acids 
 Important omega-3 fatty acids include EPA and DHA 
 Mechanisms for omega-3 fatty acids include  
-reduced inflammation due to decreased prostaglandin and 
leukotriene synthesis 
-reduced thrombosis and platelet aggregation  
-direct antiarrythmic effects in cell membranes 
 Large studies confirm that omega-3 fatty acid intake reduces 
cardiovascular disease and sudden death 
 The American Heart Association recommends eating fish twice 
a week, and daily intake of 1 g EPA and DHA to reduce 
cardiovascular disease 
Vitamin E 
 Vitamin E is an essential fat soluble vitamin that is an 
antioxidant 
 Animal studies do not uniformly show beneficial effects 
 Vitamin E reduced cardiovascular risk in two studies (CHAOS 
and SPACE), but not in others (GISSI, HOPE-TOO) 
 Vitamin E supplementation has been associated with higher 
incidence of heart failure, so routine supplementation with 
vitamin E is not recommended 
Phytoestrogens 
 Phytoestrogens, including soy isoflavones, are plant 
compounds with chemical structures that resemble estrogens 
 Mechanisms include improved lipid profiles and improved 
endothelial reactivity 
 Phytoestrogens may induce hormone dependent cancers 
(breast and endometrial), leading to recommendations on 
maximum daily intake
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5. Conclusions and evidence-based recommendations  
Omega-3 fatty acids have been clearly shown in epidemiological studies and clinical trials to 
reduce the incidence of cardiovascular disease. Thus, the American Heart Association 
recommends eating fish (particularly fatty fish) at least twice a week. They also recommend 
foods rich in ALA (flaxseed, canola, and soybean oils; flaxseed and walnuts). For patients 
with documented coronary heart disease, the recommended level of consumption is 1 g of 
EPA+DHA per day, either from fish (preferably), or supplementation. For subjects with 
elevated triglyceride levels, 2-4 grams of EPA+DHA is recommended as supplementation 
(Kris-Etherton et al., 2002). 
At this time, the evidence does not justify the use of vitamin E supplements for CVD risk 
reduction, both because of lack of evidence for benefit and possible adverse effect reflected 
in the increases in all-cause mortality and hemorrhagic stroke. However, a balanced diet 
with emphasis on antioxidant-rich fruits, vegetables, and whole grains is recommended 
(Kris-Etherton et al., 2004). Whether antioxidant vitamin supplements including vitamin E 
influence the development of diabetes, in which oxidative stress plays an important role, is 
not clear and warrants further investigation. 
Supplementing the diet with soy protein has failed to confirm phytoestrogens as the 
responsible agent for beneficial cardiovascular effects. Furthermore, soy phytoestrogens 
may increase carcinogenesis. Thus, isoflavone supplements are not currently recommended 
(Sacks et al., 2006). Soy foods may still be beneficial to cardiovascular and overall health 
because of their high content of polyunsaturated fats, fiber, vitamins, and minerals and low 
content of saturated fat (Krauss et al., 2000). 
Epidemiologic evidence has suggested an array of potentially beneficial compounds in 
foods. While there have been many mechanistic studies in the laboratory or in animal 
models, large scale randomized controlled clinical trials are necessary to prove or disprove 
their effects on health and safety, particularly in light of possible toxicities. Until the results 
of such studies are available, a diet consistent with American Heart Association 
recommendations (Kris-Etherton et al., 2004), with emphasis on antioxidant-rich fruits, 
vegetables, and whole grains, appears to be the most sensible approach. 
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